B. Riley Financial Cuts biote (NASDAQ:BTMD) Price Target to $2.00

Key Points

• B. Riley cut its price target on biote to $2.00 (from $3.00) and maintained a "neutral" rating — the new target implies about a 27.8% upside from the stock’s prior close, while the Street consensus remains a "Hold" with an average target of $4.00.
• Shares fell roughly 9.0% to $1.57, trading near their 52‑week low and below the 50‑ and 200‑day moving averages; the company slightly beat Q4 EPS and revenue but issued FY2026 revenue guidance below Street expectations and shows a negative return on equity, factors likely weighing on the stock.

biote (NASDAQ:BTMD - Get Free Report) had its target price reduced by B. Riley Financial from $3.00 to $2.00 in a research note issued on Thursday,Benzinga reports. The brokerage presently has a "neutral" rating on the stock. B. Riley Financial's price objective would suggest a potential upside of 27.80% from the stock's previous close.

BTMD has been the subject of a number of other research reports. Weiss Ratings restated a "sell (d+)" rating on shares of biote in a research report on Monday, December 29th. TD Cowen reiterated a "buy" rating and set a $2.50 price target (down from $3.00) on shares of biote in a research report on Thursday. National Bank Financial set a $2.50 price objective on shares of biote in a report on Thursday. Finally, Truist Financial set a $5.00 price objective on shares of biote in a research note on Wednesday, January 7th. Two research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company has a consensus rating of "Hold" and an average price target of $4.00.

biote Stock Down 9.0%

Shares of NASDAQ BTMD traded down $0.16 during mid-day trading on Thursday, reaching $1.57. 264,727 shares of the company were exchanged, compared to its average volume of 170,229. biote has a 52 week low of $1.54 and a 52 week high of $4.75. The company's 50 day moving average price is $2.20 and its 200 day moving average price is $2.65. The stock has a market capitalization of $71.46 million, a PE ratio of 1.98 and a beta of 1.14.

biote (NASDAQ:BTMD - Get Free Report) last released its earnings results on Wednesday, March 11th. The company reported $0.06 EPS for the quarter, beating analysts' consensus estimates of $0.05 by $0.01. biote had a negative return on equity of 21.86% and a net margin of 14.72%.The business had revenue of $46.41 million for the quarter, compared to analysts' expectations of $45.79 million. On average, sell-side analysts predict that biote will post 0.75 earnings per share for the current year.

Institutional Investors Weigh In On biote

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Fisher Asset Management LLC bought a new position in biote in the third quarter worth about $30,000. Quadrature Capital Ltd purchased a new position in shares of biote during the 2nd quarter worth approximately $41,000. LPL Financial LLC bought a new position in shares of biote in the 4th quarter worth approximately $32,000. AQR Capital Management LLC bought a new position in shares of biote in the 1st quarter worth approximately $43,000. Finally, Jane Street Group LLC purchased a new position in shares of biote in the 2nd quarter valued at approximately $53,000. 21.68% of the stock is currently owned by institutional investors.

Trending Headlines about biote

Here are the key news stories impacting biote this week:

• Positive Sentiment: biote beat Q4 expectations on both EPS and revenue — reported EPS ~$0.063 vs. ~$0.05 expected, and revenue of $46.41M vs. ~$45.8M expected, demonstrating underlying operational resilience. Q4 & FY2025 Results
• Positive Sentiment: Management projects 2026 revenue above $190M and highlighted plans to expand the sales force and invest in its technology platform — moves that could support topline acceleration if execution matches the plan. Article: 2026 revenue guidance & investments
• Neutral Sentiment: Management reiterated its strategic priorities focused on sustainable, profitable growth — a positive directional signal but dependent on execution and timing. MarketIsOpen: Strategic priorities
• Neutral Sentiment: Multiple outlets published the Q4 earnings call transcript and highlights (useful for hearing management’s tone and cadence). Earnings call transcript
• Negative Sentiment: FY2026 revenue guidance (~$190.0M) is below the Street consensus (~$195.4M), which likely pressured the stock despite the beat — investors often react negatively to guidance that trails estimates. Guidance note
• Negative Sentiment: Company metrics show a mixed profitability profile: a healthy net margin was reported, but return on equity remains negative (-21.86%), which could concern investors focused on capital efficiency. MarketBeat profile
• Negative Sentiment: Technicals are weak relative to recent trading: shares sit below the 50‑ and 200‑day moving averages and near their 12‑month low — a factor that can amplify downside in a risk‑off session. Price performance & moving averages

biote Company Profile

biote Corp. operates in practice-building business within the hormone optimization space. It trains physicians and nurse practitioners in hormone optimization using bioidentical hormone replacement pellet therapy in men and women experiencing hormonal imbalance. The company offers Biote Method, a comprehensive end-to-end practice building platform that provides Biote-certified practitioners with the components developed for practitioners in the hormone optimization space comprising Biote Method education, training, and certification services; practice management software that allows Biote-certified practitioners to order, track, and manage hormone optimization product inventory and other administrative requirements; inventory management software to monitor pellet inventory; and information regarding available hormone replacement therapy products, as well as digital and point-of-care marketing support.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.